Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2003
08/21/2003US20030158233 Compositions and methods for treating heart failure
08/21/2003US20030158230 Povidone or copovidone binder; HCl-free or non-hygroscopic filler; oral dosage form; serotonin reuptake inhibition
08/21/2003US20030158229 Also treating bulimia nervosa, irritable bowel syndrome, urinary incontinence, asthma, bradycardia, and bradyarrhythmia
08/21/2003US20030158228 Method of correcting herg channel dysfunction
08/21/2003US20030158226 Treating or preventing emphysema, cancer and dermatological disorders
08/21/2003US20030158225 Novel compounds
08/21/2003US20030158224 Vascular endothelial growth factor receptor tyrosine kinases inhibitors; angiogenesis inhibitors, anticarcinogenic agents
08/21/2003US20030158223 Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
08/21/2003US20030158222 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents)
08/21/2003US20030158221 2-imidazomethyl- pyrido(4,3-b)indol-1-one or -carbazol-1-one derivatives containing an ester group; especially for treating irritable bowel syndrome.
08/21/2003US20030158220 Especially administered in a very low dosage such that peak plasma concentrations do not exceed 100 ng/ml.; reduces side effects such as constipation, dysphoria, pruritus, and urinary retention.
08/21/2003US20030158219 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
08/21/2003US20030158218 Amino-substituted N-(arylalkyl)amidomethyl- pyridine or pyrimidine derivative or its N-oxide
08/21/2003US20030158217 Succinate and malonate complexes treatment of abnormal cell growth, such as cancer, and overexpression of erbB2, and inducing cell death
08/21/2003US20030158216 2-acyl indole derivatives and their use as antitumor agents
08/21/2003US20030158214 Remedial agent for neural degeneration
08/21/2003US20030158213 Xanthine oxidase inhibition as a strategy to alleviate oxidative impairment of vascular function
08/21/2003US20030158211 Methods and compositions for treatment of central nervous system disorders
08/21/2003US20030158210 Amino acid ester containing azole antifungals
08/21/2003US20030158209 Amidomethylcarbonyl-substituted piperazine derivatives containing additional amine groups, useful in treating eating, sexual and skin disorders
08/21/2003US20030158208 Dopamine D4 ligands for the treatment of novelty-seeking disorders
08/21/2003US20030158207 N-benzylpiperazine compounds
08/21/2003US20030158206 Sildenafil mesylate for the treatment of male erectile dysfunction or female sexual disorders.
08/21/2003US20030158205 N-benzyl-substituted, e.g., (2S)-1-(p-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(p -fluorobenzyl)piperazine; inhibit the activity of the chemokines, MIP-1 alpha and RANTES
08/21/2003US20030158203 Triazolo-pyridazine derivatives as ligands for GABA receptors
08/21/2003US20030158202 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders
08/21/2003US20030158201 Method for treating septic shock
08/21/2003US20030158200 E.g., 6-(4-(N'-(4-hydroxy-3-methoxy-2-nitrobenzylidene)-hydrazino)phenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one
08/21/2003US20030158197 Certain alkylene diamine-substituted heterocycles
08/21/2003US20030158196 Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
08/21/2003US20030158194 Treating Congestive heart failure with a diethylamineethyloxy phenylketone benzofuran compounds
08/21/2003US20030158193 Therapeutic treatment of gastrointestinal inflammatory disorders, ulcer disorders
08/21/2003US20030158192 Activating cytokine biosynthesis, viricides treating a viral disease, antitumor agents, immunomodulators
08/21/2003US20030158191 Cannabinol derivatives
08/21/2003US20030158189 Non-steroidal antiinflammatory agents treating bone disorders, Crohn's disease, and inflammatory bowel disease, respiratory disorders such as chronic obstructive pulmonary disease, infections, autoimmune diseases
08/21/2003US20030158188 An antagonists for treating pain, inflammations, urinary incontinence and bladder overactivity
08/21/2003US20030158187 Genetic polymorphisms in the preprotachy kinin gene
08/21/2003US20030158186 Compositions and methods for treating heart failure
08/21/2003US20030158185 Novel use of phenylheteroakylamine derivatives
08/21/2003US20030158184 Treating male impotence, sexual disorders; donates, transfers or releases nitrogen monoxide
08/21/2003US20030158183 Method of treating schizophrenia
08/21/2003US20030158182 Cyanopyrroles
08/21/2003US20030158181 Method for treating cerebral ishaemia
08/21/2003US20030158179 Quinoline derivatives
08/21/2003US20030158178 Heterocyclic retinoid compounds
08/21/2003US20030158177 Treating or preventing obesity
08/21/2003US20030158176 Quaternary ammonium compounds
08/21/2003US20030158175 Chroman derivatives as 5-hydroxytrytamine-6 ligands
08/21/2003US20030158174 Crystalline 1-methylcarbapenem derivatives
08/21/2003US20030158173 NK 1 antagonists
08/21/2003US20030158172 Treatment of behavioral disorders and cognitive activators by administering carboxypeptidase E enzyme inhibitors, penam and cephem beta -lactam antibiotics
08/21/2003US20030158171 A metal complexes with carnitine, naturally occurring amino acids, thiamine for treating drug abuse, drug dependence
08/21/2003US20030158169 Method of treating hemorrhagic shock or systemic inflammatory response syndrome
08/21/2003US20030158168 Composition for combined use of aromatase inhibitors
08/21/2003US20030158167 2-substituted ring A aromatic sterol derivatives having a comparatively short 17-position hydrocarbyl side chain terminates in an carboxaldehyde or hydroxy group; antiproliferative and antiangiogenic agent
08/21/2003US20030158166 Administration of an anticancer (7-alpha-9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl)-estra-1,3,5,-(10) triene-3,17-diol to a breast cancer patient previously treated with an aromatase inhibitor and failed
08/21/2003US20030158165 Wound treatment solution and method for using same
08/21/2003US20030158164 Novel antiandrogenic agent
08/21/2003US20030158163 Conversion of carboxylic acid substituent in a gonane ring, into the methyl ester, or hydrochlorination of a 9-11-epoxy-9-H-cyclopenta(a)phenanthrene compounds
08/21/2003US20030158162 Administering a therapeutically effective amount of an epoxy-steroidal aldosterone receptor antagonist that contains a 9,11-epoxy group to the patient for reducing intraocular pressure
08/21/2003US20030158161 Administering to the human patient or non- human animal an effective amount of a substituted spirostan derivative to treat neurodegenerative disorders
08/21/2003US20030158160 Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
08/21/2003US20030158159 Administering a calcitonin-like agent and a dehydroepiandrosterone-like agent to treat an indivisual for bone density loss
08/21/2003US20030158158 1 alpha, 25-dihydroxy-22-oxavitamin D3 (OCT) and a pH modifier, excellent stability; in vitro differentiation inducing activity, useful for treating secondary hyperparathyroidism, psoriasis and other diseases
08/21/2003US20030158157 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
08/21/2003US20030158156 Exposing the Gram positive bacteria to an heterocyclic ether compound or an aromatic compound containing amine, ether, hydrocarbon, ester or ketone groups linked by two benzene rings, capable of inhibiting toxic shock syndrome toxin
08/21/2003US20030158154 Vitamin D derivative is selected from calcitriol, alphacalcidol, 24,25-dihydroxy vitamin D3, and calcifediol, and bisphosphonate such as alendronic acid or salts or hydratess for bone disorders; improved combination
08/21/2003US20030158153 2-(1h-indol-3-yl)-2-oxo-acetamides with antitumor activity
08/21/2003US20030158152 Protease inhibitors and their pharmaceutical uses
08/21/2003US20030158150 Combination therapy to treat hepatitis B virus
08/21/2003US20030158149 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold
08/21/2003US20030158148 Administering to a cancer patient a 20(S)- camptothecin for a period of time during which a pyrimidine base analog such as 5-fluorouracil or 5-fluorocysteine in not being administered and administering the pyrimidine base to the cancer patient
08/21/2003US20030158147 Method for treating pain
08/21/2003US20030158146 Chemical compounds
08/21/2003US20030158145 6-((2,2- diphenylethyl)amino)-9-(N-ethyl- beta -D-ribofuranosyluronamide)-N--(2-(N'-(1-(2-pyridyl)-4 -piperidyl)ureido)ethyl)-9H-purine-2-carboxamide
08/21/2003US20030158143 For treatment of endocrine-regulated tumors, for example, breast, prostate, ovarian and colon cancers
08/21/2003US20030158138 Nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
08/21/2003US20030158130 Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
08/21/2003US20030158128 Treatment, composition and method using uracil against side-effects of chemotherapy
08/21/2003US20030158126 Plant compounds menthol and menthyl acetate when mixed at specific concentrations enhance antifungal activity of commercially available fungicides
08/21/2003US20030158125 Polysaccharidic esters of n-derivatives of glutamic acid
08/21/2003US20030158124 Functionalized with aliphatically unsaturated, hydroxy reactive compound selected from carboxylic acid, carboxylic acid ester, isocyanate, epoxide; useful in crosslinked form as extractant in beverage clarification
08/21/2003US20030158122 For treatment of hyperlipidemia and blood coagulation disorders and to reduce levels of virus, bacteria, and endotoxins in blood stream
08/21/2003US20030158121 Novel $G(y)crystalline form of perindopril tert- butylamine salt, preparation method, and pharmaceutical compositions containing same
08/21/2003US20030158119 Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on
08/21/2003US20030158118 For therapy of cancer, chemoprevention or the suppression of hypersensitivity and inflammatory reactions
08/21/2003US20030158117 Coniosulfides and their derivatives, processes for preparing them, and their use as pharmaceuticals
08/21/2003US20030158114 Administering to a subject in need of such treatment, an agent in an amount effective to inhibit proliferation
08/21/2003US20030158105 Determining polypeptide sequence of at least one Bcr-Abl polypeptide expressed by the human cancer cell and comparing the polypeptide sequence of the Bcr-Abl polypeptide expressed by the human cancer cell to the Bcr-Abl polypeptide sequence
08/21/2003US20030158099 Cancer therapy
08/21/2003US20030158097 P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine
08/21/2003US20030158094 Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product
08/21/2003US20030158090 Renin-angiotensin system in diabetes mellitus
08/21/2003US20030158088 For therapy of solid tumors and human immunodeficiency virus infected cells
08/21/2003US20030157669 Ansamitocins
08/21/2003US20030157633 Comprises nucleotide sequences coding transmembrane protein/transport protein (TRPV3) for treating pain, inflammation and skin disorders
08/21/2003US20030157599 Comprises nucleotide sequence coding prostaglandin E receptor (EP3) for diagnosis and treatment of atherosclerotic diseases; restriction fragment length polymorphisms
08/21/2003US20030157572 Determining phosphorylation state of a serine corresponding the residue 1981 of Ataxia-Telangiectasia Mutated kinase protein in a cell; the phosphorylation state of serine is indicative of activation state of ATM kinase
08/21/2003US20030157560 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
08/21/2003US20030157552 Providing a screening assay having stearoyl-CoA desaturase biological activity, contacting sceening assay with a test compound and measuring the biological activity
1 ... 5368 5369 5370 5371 5372 5373 5374 5375 5376 5377 5378 5379 5380 5381 5382 5383 5384 5385 5386 5387 5388 ... 7860